Ojetti, V., Petruzziello, C., Migneco, A., Gnarra, M.,
Gasbarrini, A., & Franceschi, F. (2017).
Effect of Lactobacillus reuteri (DSM 17938) on methane
production in patients affected by functional constipation:
A retrospective study.
Oliveira, M., Bosco, N., Perruisseau, G., Nicolas, J.,
Segura-Roggero, I., Duboux, S., Briand, M., Blum, S.,
& Benyacoub, J. (2011).
Lactobacillus paracasei reduces intestinal inflammation
in adoptive transfer mouse model of experimental colitis.
Riezzo, G., Orlando, A., D’Attoma, B., Linsalata, M.,
Martulli, M., & Russo, F. (2018).
Randomised double blind placebo controlled trial on
Lactobacillus reuteri DSM 17938: Improvement in symptoms
and bowel habit in functional constipation.
Schepper, J. D., Collins, F. L., Rios-Arce, N. D.,
Raehtz, S., Schaefer, L., Gardinier, J. D.,
Britton, R. A., Parameswaran, N., & McCabe, L. R. (2019).
Probiotic Lactobacillus reuteri prevents postantibiotic
bone loss by reducing intestinal dysbiosis and preventing
barrier disruption.
Venkataraman, B., Almarzooqi, S., Raj, V.,
Alhassani, A. T., Alhassani, A. S., Ahmed, K. J.,
Subramanian, V. S., Ojha, S. K., Attoub, S.,
Adrian, T. E., & Subramanya, S. B. (2021).
Thymoquinone, a dietary bioactive compound, exerts
anti-inflammatory effects in colitis.